Cardiovascular Diseases in the Patients With Psoriatic Arthritis

Akhlaq, Anum; Ali, Huma; Sheikh, Abu Baker; Muhammad, Hafiz; Ijaz, Sardar Hassan; Sattar, Muhammad; Nazir, Salik; Din, Mian Tanveer Ud; Nasir, Usama; Khan, Muhammad Zia; Muslim, Muhammad; Wazir, Muhammad Hisham Khan; Dani, Sourbha S.; Fudim, Marat; Minhas, Abdul Mannan Khan

doi:10.1016/j.cpcardiol.2022.101131

Cited by 4 publications

(2 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…до 1,7 % (2011, 2012, P-тренд = 0,248) и статистически незначимое увеличение до 2,3 % (2017, 2018, P-тренд = 0,056). По результатам исследования выявлена тенденция к увеличению числа госпитализаций по поводу ССЗ у пациентов с ПсА [8].…”

Section: сердечно-сосудистые заболевания у больных воспалительными ар...unclassified

Cardiovascular risk in patients with inflammatory arthritis

Anichkov,

Shostak,

Timofeev

2024

Klinicist

View full text Add to dashboard Cite

Rheumatoid and other inflammatory arthritis (ankylosing spondylitis and psoriatic arthritis) have a high risk of cardiovascular disease (CVD). It is caused by the accelerated development of atherosclerosis associated with a chronic systemic inflammatory process. Nevertheless, traditional CVD risk factors (hypertension, smoking, dyslipidemia) are also important for patients with inflammatory arthritis. The greatest amount of data has been accumulated regarding the relationship between CVD and rheumatoid arthritis. Due to the difficulties in diagnosing coronary heart disease and other CVD, it is of great importance to identify patients at high and very high risk. The use of scales for assessing the total cardiovascular risk SCORE/SCORE 2 with a coefficient of 1.5 allows to identify patients who need measures to reduce their high risk of CVD. Control of the of the disease activity, lifestyle modification, therapy with statins and antihypertensive drugs in accordance with current guidelines, caution when prescribing non-steroidal anti-inflammatory drugs and minimizing the dose of glucocorticoids are the main components of the strategy for reducing the risk of CVD in patients with inflammatory arthritis.

show abstract

Section: сердечно-сосудистые заболевания у больных воспалительными ар...unclassified

Cardiovascular risk in patients with inflammatory arthritis

Anichkov,

Shostak,

Timofeev

2024

Klinicist

View full text Add to dashboard Cite

show abstract

“…Recent studies indicate that PsA, afflicting up to 30% of psoriasis patients, has a prevalence of 6-25 cases per 10,000 individuals in the American population ( 2 ). Although PsA primarily manifests in joint pathology, emerging evidence suggests that patients with PsA are at higher risk for cardiovascular diseases, respiratory disorders, and malignancies ( 3 , 4 ). Moreover, PsA significantly impacts patients’ physical and mental health and imposes substantial financial burdens.…”

Section: Introductionmentioning

confidence: 99%

Plasma proteins and psoriatic arthritis: a proteome-wide Mendelian randomization study

Zhao,

Zhou,

Wang

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

BackgroundPrevious epidemiological studies have identified a correlation between serum protein levels and Psoriatic Arthritis (PsA). However, the precise nature of this relationship remains uncertain. Therefore, our objective was to assess whether circulating levels of 2,923 plasma proteins are associated with the risk of PsA, utilizing the Mendelian randomization (MR) approach.MethodsTwo-sample MR analysis was performed to assess the causal impact of proteins on PsA risk. Exposure data for plasma proteins were sourced from a genome-wide association study (GWAS) conducted within the UK Biobank Pharma Proteomics Project, which encompassed 2,923 unique plasma proteins. The outcome data for PsA were sourced from the FinnGen study, a large-scale genomics initiative, comprising 3,537 cases and 262,844 controls. Additionally, colocalization analysis, Phenome-wide MR analysis, and candidate drug prediction were employed to identify potential causal circulating proteins and novel drug targets.ResultsWe thoroughly assessed the association between 1,837 plasma proteins and PsA risk, identifying seven proteins associated with PsA risk. An inverse association of Interleukin-10 (IL-10) with PsA risk was observed [odds ratio (OR)=0.45, 95% confidence interval (CI), 0.28 to 0.70, PFDR=0.072]. Additionally, Apolipoprotein F (APOF) has a positive effect on PsA risk (OR=2.08, 95% CI, 1.51 to 2.86, PFDR=0.005). Subsequently, we found strong evidence indicating that IL-10 and APOF were colocalized with PsA associations (PP.H4 = 0.834 for IL-10 and PP.H4 = 0.900 for APOF). Phenome-wide association analysis suggested that these two proteins may have dual effects on other clinical traits (PFDR<0.1)ConclusionThis study identified 7 plasma proteins associated with PsA risk, particularly IL-10 and APOF, which offer new insights into its etiology. Further studies are needed to assess the utility and effectiveness of these candidate proteins.

show abstract